Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.
Lung cancer (Amsterdam, Netherlands)（2023）
摘要
The combination of SBRT to the primary tumor and double immunotherapy in advanced NSCLC patients is safe and feasible.
更多查看译文
关键词
Immunotherapy,Non-small cell lung cancer,Resistance,Safety,Stereotactic body radiotherapy,Tolerability
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要